Daiichi Sankyo: European observational study SANTORINI shows LDL-C levels remain higher than recommended goals and combination therapies are under-utilised in patients at very high or high cardiovascular risk finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Novartis products will remain available at all pharmacies despite the UK no longer being part of the EU single market for pharmaceuticals, the company’s r
Parallel submission of generic applications gov.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gov.uk Daily Mail and Mail on Sunday newspapers.
Interim Statement by the Malta Medicines Authority on AstraZeneca COVID-19 Vaccine (Vaxzevria) maltawinds.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from maltawinds.com Daily Mail and Mail on Sunday newspapers.
Marketing authorisations for veterinary medicines gov.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gov.uk Daily Mail and Mail on Sunday newspapers.
Joint labelling for veterinary medicines for use in the UK and Ireland Guidance for the veterinary pharmaceutical industry on how to apply for and maintain a joint-label for use on veterinary medicines placed on the market in the UK and Ireland. From: Eligible Marketing Authorisations and criteria Joint-labelling allows for a single label/leaflet that has been agreed by the VMD, on behalf of the UK, and the Health Products Regulatory Authority ( HPRA), on behalf of Ireland, for use on veterinary medicines marketed in their countries. Joint labelling could be achieved between GB and IE, NI and IE or all three - GB, IE and NI. You should also refer to the
Brief description of the problem SyriMed are recalling the above batch as a precautionary measure due to an issue related to the container closure (child-lock cap). The Marketing Authorisation Holder has received a number of complaints related to defective container closures and the investigation has identified an issue with the bottle capping during the manufacturing process for this batch only. Advice for healthcare professionals Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process. Further Information For more information or medical information queries, please contact: customer.services@syrimed.co.uk.
Register to make submissions to the MHRA Submissions related to human medicines need to be submitted directly to the MHRA. From: Contents Print this page For applications that you plan to submit to the UK (for example, a Marketing Authorisation for the UK or GB market), you will need to submit the information through our national portals. For those regulatory submissions made through European procedures you will need to continue to submit via the EU portals (for example, CESP). The information on how to make submissions to the MHRA is for the following groups: all pharmaceutical companies involved in making medicines regulatory submissions and vigilance activities for UK/GB licences
Registering to make submissions to the MHRA from 1 January 2021 gov.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gov.uk Daily Mail and Mail on Sunday newspapers.